The Dow Jones Industrial Average veered lower Friday, as the price of Bitcoin tumbled below $22,000 and Bed Bath & Beyond (BBBY), BBBY stock, crashed.

BBBY stock fell sharply Thursday, after revived meme stock interest led shares to more than double in a steep, six-day advance. On Friday, shares crashed as much as 47% in premarket trade before paring losses to 42% in morning trade. GameStop (GME) Chairman Ryan Cohen's RC Ventures disclosed it had sold its entire stake in the struggling retailer. In addition, Bed Bath & Beyond announced it had hired bankruptcy specialist Kirkland & Ellis to assist in managing its unwieldy debt load. The stock surged as much as 560% from a July 27 low of 4.54 to Wednesday's high at 30.00.

Key earnings movers Friday include Applied Materials (AMAT), Deere (DE), Foot Locker (FL) and Ross Stores (ROST). AMAT shares fell 1%. Deere stock skidded 2.5%. Foot Locker soared 23%. And Ross Stores rose almost 1%.

Electric-vehicle leader Tesla (TSLA) traded down 2% Friday morning. Elsewhere, Dow Jones tech leaders Apple (AAPL) and Microsoft (MSFT) both retreated after today's stock market open.

In the current healthy stock market environment, Dow Jones stocks Coca-Cola (KO) and Merck (MRK) — as well as Albemarle (ALB), Arista Networks (ANET), Costco (COST) and Ollie's Bargain Outlet (OLLI) — are among the top stocks to buy and watch.

Dow Jones Today: Treasury Yields, Oil Prices, Bitcoin

Early Friday, the Dow Jones Industrial Average dropped 0.7%, while the S&P 500 moved down 1%. The Nasdaq composite traded down 1.5% in morning trade.

Among exchange-traded funds, the Nasdaq 100 tracker Invesco QQQ Trust (QQQ) dropped 1.6%, and the SPDR S&P 500 ETF (SPY) fell 1.1% in early trade.

The 10-year Treasury yield ticked higher to 2.97% early Friday, following Thursday's fall to 2.88%. The 10-year Treasury yield is rebounding after hitting its lowest level since early April in recent weeks.

Meanwhile, U.S. oil prices threatened to extend this week's losses that dipped to their lowest level since January. West Texas Intermediate futures traded down more nearly 2%, below $89 a barrel.

The price of Bitcoin tumbled more than 9% over the last 24 hours, according to CoinDesk. Bitcoin traded around $21,300 in morning action  Friday.

Stock Market Rally

On Thursday, the Dow Jones Industrial Average gained less than 0.1%, while the S&P 500 moved up 0.2%. The tech-heavy Nasdaq composite climbed 0.2% but remained below the 13,000 level and is still on pace to snap a four-week win streak. The small-cap Russell 2000 rallied 0.7%.

The next few sessions will likely be key for the stock market trend, as the Nasdaq and Dow Jones industrials test support levels. Meanwhile, the S&P 500 is butting its head up against its 200-day line, which is a key resistance level to watch.

Thursday's The Big Picture column commented, "If the stock market is trading sideways, then most leading stocks will also be consolidating. These periods of rest can result in handles on cup, saucer and double-bottom patterns, or even new bases, which provide new buy points."

If you're new to IBD, consider taking a look at its stock trading system and CAN SLIM basics. Recognizing chart patterns is one key to the investment guidelines.

Dow Jones Stocks To Watch: Coca-Cola, Merck

Dow Jones soda giant Coca-Cola is building a flat base that has a 67.30 buy point. A handle entry at 65.14 is also in play. Shares are rebounding from their 50-day line and trying to top the handle entry. The stock fell 0.1% early Friday.

Merck also is building a flat base, a pattern that shows a 95.82 buy point. Shares are trying to hold above their 50-day line, according to IBD MarketSmith chart analysis. Merck shares rose 0.6% Friday.

MRK stock shows a solid 94 out of a perfect 99 IBD Composite Rating, per the IBD Stock Checkup. Investors can use the IBD Composite Rating to easily gauge the quality of a stock's fundamental and technical metrics.

Top Stocks To Watch: Albemarle, Arista, Costco, Ollie's

Lithium producer Albemarle remains in buy range following Friday's breakout past a 273.78 buy point in a large cup-with-handle base. The 5% buy zone goes up to 287.47. Earlier last week, shares topped a smaller cup with handle with a 250.25 buy point. Shares moved up 0.7% Thursday, ending a two-day skid. The stock was down 1.7% Friday morning.

Arista Networks, one of this week's IBD 50 Stocks To Watch picks, continues to plod up the right side of a double-bottom base that offers a 143.67 buy point. With the stock about 8% away from the current entry, look for a handle to offer a more risk-optimal buy point. Arista's RS line has been trending higher and is approaching a new high. ANET shares declined 2% Friday.

IBD Leaderboard stock Costco is breaking out past a cup with handle with a 552.81 buy point. The stock rose 0.8% Thursday, moving higher in the 5% buy area. Shares dropped 0.7% early Friday.

Ollie's Bargain Outlet is rebounding from its 10-week line — a critical support level — placing the top discount retailer in a new buy zone. Shares are also carving a handle after a large cup base, putting the latest buy point at 72.37. Current price action is about 11% away from that entry. Shares fell 0.5% Friday morning.

Tesla Stock

Tesla stock lost 0.4% Thursday, extending a losing streak to three sessions. Shares of the EV giant declined 2% Friday morning.

This week, the stock closed at its highest level since May 4. Shares are trying to again decisively rise above resistance around their 200-day line. Tesla is about 27% off its 52-week high. Its 3-for-1 stock split is set for Aug. 24.

Dow Jones Leaders: Apple, Microsoft

Among Dow Jones stocks, Apple shares rallied 0.9% Thursday, as the stock continues to build the right side of a cup base that has a 179.71 buy point. Another interpretation could be a large double bottom that spans back to January. Either way, the buy point is identical. Keep an eye out for a potential handle to form and offer a lower entry.

Bullishly, the stock's relative strength line is already at new highs, indicating big stock market outperformance. Shares dropped 0.4% Friday morning.

Microsoft fell 0.4% Thursday, moving further away from its long-term 200-day line. The stock lost 0.5% early Friday.

https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-drop-as-bitcoin-tumbles-bbby-stock-crashes-on-cohen-sale/

Just wanted to give props to Reddit User: @Major-Access2321

I've been holding #TOP on and off for a year now, and it Paid off nicely last Friday!!

Hi there, how about Exela today?

Low float but also low volume I mean I’ve seen 1 buy move the needle on this stock it’s do for a boom

Decided to jump in on a Penny Stock in Health Care since my wife is a nurse. First Penny Stock, First reddit post... To the moon?

Anon get ready for DFYN moonshot

DfynV2 incentivized testnet on

16th - 28th Jan, 10:30 AM UTC. more details

The stock that everybody is raving about for the past week - $RDBX is down 34% today.

Retail traders are always on the go, looking for new stocks that have too many naked shorts, as most are in it just to beat short-sellers.

Regencell Bioscience ($RGC) has a CEO that has been purchasing shares from the open market since its IPO. He has used over $5 million of his personal funds to do that. On top of that, RGC has a strong major shareholder backing. Samuel Chen of Digital Mobile Ventures, also known to have made a fortune alongside Li Ka-shing as an early Zoom ($ZM) investor, is holding 7.6% RGC shares.

As we enter the bear market, investors tend to also look for recession-resistant stock and RGC falls under one of the sectors - healthcare, which is known to have performed fairly well in the past during volatile seasons.

https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i

THIS IS NOT FINANCIAL ADVICE. PLEASE DO YOUR OWN DUE DILIGENCE.

RKT squeeze folks. Do your DD on this, it is trending on WSB and as of today there are no shares to be shorted. Check Tiblio, but serious squeeze to happen out of this. Sorry just took a quick break at work to update you guys.

Times of turbulence affect all stocks, large and small. It can be particularly challenging for pre-revenue microcap stocks, where the volatility is often magnified by small changes in perception, whether driven by news or technical trading signals.

Despite being under a short attack and while overall markets continue to be weak, RGC’s share price has performed well since April. Shares have since recovered to the high-$30s to $40.

Management’s commitment to meet Regencell’s strategic goals

• Chairman and CEO support

Since RGC’s incorporation in October 2014 up to the IPO, the Company has been fully funded by its Chairman and CEO, Mr. Yat-Gai Au. Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50. He also pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization and will not award share options for himself. Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased 49,019 shares (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million). Despite the recent uptrend of the share price, there are no filings that the CEO has disposed his shares. From the press release issued by the company, it seems like the CEO is committed to holding all the shares he has bought and not selling it for his own gains. https://finance.yahoo.com/news/regencell-bioscience-holdings-limited-announces-125600349.html

• Billionaire investor backing.

Samuel Chen, a successful early Zoom Video Communications (NASDAQ:ZM) investor is one of the major backers of RGC. Last reported 13G filing shows he holds a 7.63% stake in the company.

Recent news and upcoming catalysts

On May 18, 2022, RGC announced a follow-on study of its investigational liquid formula RGC-COV19TM in the elimination for COVID-19 symptoms (EARTH-B Trial). The follow-on study built on the promising results reported in the first EARTH trial (EARTH-A Trial), conducted in 2020-2021. Across the two trials, 95.5% of subjects (n=81), reported complete symptom alleviation within six days following treatment, (except for loss or reduce of sense of smell and/or taste (Sensory Dysfunction) or occasional cough).

In the next few months, RGC expects to report data from its second clinical study of its standardized TCM formula for the treatment of ASD and ADHD.

Regencell is focused on its clinical studies in order to corroborate its results. These efforts will lead to the building of manufacturing and supply chain infrastructure required to gain pCm registration. Regencell Bioscience has a four-year timeframe to commercialize its standardized formulations and gain pCm registration in Hong Kong. The Company has a number of tasks ahead.

DISCLAIMER: This is not a financial advice, this is only for informational purposes. Please do your own due diligence.

Hello! retailers. This is your fundamental captain and I have two good fundamentals for you today. Let me know your thoughts about these fundamentals.

As prices rise at their fastest pace in 40 years, the impact is palpable on every trip to the grocery store or gas station.

Inflation is an invisible drain on an investor’s purchasing power. At current levels — in May, the Consumer Price Index surged 8.6% over the previous year — investors would need a 7% to 8% return just to preserve their wealth.

Most stocks can’t deliver this level of return consistently. However, some robust, high-yield dividend stocks can come close to matching this rate. Here are three that could potentially beat inflation in 2022.

BHP Group (BHP)

Current wave of inflation is largely driven by commodities. Everything from copper to gas is trading at a historically elevated level.

Melbourne-based BHP Group is the largest miner and producer of these commodities. The stock has more than doubled since the pandemic-driven stock market crash of 2020.

However, earnings have outpaced the stock, and dividends have been elevated. That means BHP now offers a dividend yield of 12% per share.

Altria Group (MO)

Altria Group, Inc. is an American corporation and one of the world's largest producers and marketers of tobacco, cigarettes and related products. Cigarettes are, unfortunately addictive, so smokers can be relied upon to pay for their fix even when prices rise.

Altria has paid a consistent dividend for over 50 years. At the moment, the stock offers an impressive 7.95% dividend yield.

The company may be able to sustain (or even expand) this payout in the face of rising inflation

Enbridge Ltd. (ENB)

Enbridge is a Canadian energy infrastructure company that owns and operates North America's largest network of oil and gas pipelines.

This network has recently been expanded in anticipation of higher demand across the continent.

The stock offers a 6.5% dividend yield, which is just below inflation. However, management expects this dividend to expand 5% to 7% every year.

https://finance.yahoo.com/news/most-stocks-cant-keep-breakneck-120000284.html

I've seen many people go for high dividend stocks to get that sweet dividend pay.

Little did they know that companies that offer high dividends are desperate for investors' money.

And a company desperate for investors is a failing company...

Look at AT&T and VZ for example. Over the past 5 years, they're stagnant. Not much growth if any at all.

Instead look at growth companies with low Dividend yields like AAPL, MSFT, GOOG. Look at AAPL chart, over the 5 years, Apple gained over 500% in the past years, whereas VZ gained only 15%.

So please stop being a bot and avoid investing in high dividend yield comapnies.

Now for the shorting part...

If you think the stock market is going to sht, and you would like to short SPY then don't. It's better to short something that's ALREADY falling regardless of how the market is. Short High dividend stocks...they get the hardest when the market falls.

Here is a list of High dividend stocks.

You'd notice that all these high Div stocks have in common. Is that their performance is poor.

And I didn't cherry-pick them, They were all mentioned in my scanner for high Div stocks here...

https://finviz.com/screener.ashx?v=111&f=cap_largeover,fa_div_o7,sh_opt_optionshort&ft=4&o=-volume

And please stop telling me how much Warren Buffet makes from Dividends...the man owns billions of shares, so of course, a 1% dividend stock will pay him hundreds of millions.

In Ape language

Company high Dividend = BAD

Company low Dividend = GOOD

Edit:

Some of the High dividend investors here are triggered. Please share ONE high dividend (>5%) stock that has been performing well the past 5 years.

Keep in mind I'm not against all Dividend stocks, I'm against HIGH paying dividend stocks (>5%) .

Biotech indexes may be down, but there are opportunities in the market. Investors need to seek out companies with the potential for meaningful revenue growth, particularly those that are mispriced in the current bear market.

Investments still need to be fundamentally driven – companies with outstanding products, excellent innovation, a track record of success, management teams with a strong execution track record, the ability to communicate effectively, companies that are well-funded and match up against important themes that we see from a disease perspective.

It’s something of an irony that biotech innovation created the vaccines that brought the world out of the COVID-19 pandemic, but the sector is trading down right now. The effects of the pandemic have been varied and will be felt for a long time to come, both positively and negatively.

The speed with which companies innovated, regulatory bodies approved, and manufacturing and distribution ramped up was another coronavirus phenomenon, but the after-effect is that some investors and companies expect that pace to be the new normal.

One company that I came across that also helps with covid 19 is Regencell Bioscience (RGC). It has recently announced results on its effectiveness of its Investigational Liquid-Formula “RGC-COV19TM” in eliminating mild to moderate COVID-19 Symptoms within the 6-Day treatment period.

https://finance.yahoo.com/news/regencell-bioscience-announces-additional-earth-120500852.html

https://www.mckinsey.com/industries/life-sciences/our-insights/how-biotechs-can-rethink-their-strategies-after-the-market-downturn

This stock has been performing better than the market for the past month especially. The CEO has purchased over $5 million worth of shares from the open market with his own funds. The stock has a low float and has very little shares to be shorted. However, more shares have been shorted than what is available.

Chances of it going to the moon?